Edwards play well outside home turf; S&N's recon unit rides high for Q4
This article was originally published in Clinica
Ophthalmic company Alcon rounded off fiscal 2007 with a strong fourth quarter performance. The Swiss incorporated company's surgical business enjoyed high growth in sales for its intraocular lenses (+24.3%), cataract and vitreoretinal products (+16.1%) and devices for refractive surgery (+75.4%) Refractive revenue was boosted by a $15.1m contribution from German refractive laser company WaveLight, of which Alcon became a majority shareholder in November 2007.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.